U.S. Markets closed

Athersys reports on progress in Phase 2 study of MultiStem for ischemic stroke

Athersys recently completed enrollment of the first patient cohorts of its Phase 2 study of MultiStem, a novel adult stem cell therapy being developed by Athersys, administered to patients within approximately 1 to 2 days after they have experienced an ischemic stroke. The independent safety committee reviewed data from these patients, finding that both of the doses evaluated were safe and well tolerated, and therefore, recommended proceeding with high dose administration to patients for the remainder of the trial. The study is currently being conducted at multiple centers throughout the U.S.